Barnes Nick Peter
Northampton General Hospital, Northampton, UK.
BMJ Clin Evid. 2011 Apr 11;2011:0318.
Diagnosis of migraine headache in children can be difficult as it depends on subjective symptoms; diagnostic criteria are broader than in adults. Migraine occurs in 3% to 10% of children and increases with age up to puberty. Migraine spontaneously remits after puberty in half of children, but if it begins during adolescence it may be more likely to persist throughout adulthood.
We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments for acute attacks, and of prophylaxis for migraine headache in children? We searched: Medline, Embase, The Cochrane Library, and other important databases up to June 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
We found 22 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
In this systematic review we present information relating to the effectiveness and safety of the following interventions: for acute symptom relief (antiemetics, codeine phosphate, non-steroidal anti-inflammatory drugs [NSAIDs], paracetamol, and 5HT1 antagonists [such as triptans]) and for prophylaxis (beta-blockers, dietary manipulation, pizotifen, progressive muscle relaxation, stress management, thermal biofeedback, and topiramate).
儿童偏头痛的诊断可能具有挑战性,因为其依赖于主观症状;诊断标准比成人更为宽泛。3%至10%的儿童患有偏头痛,且发病率随年龄增长直至青春期。一半儿童的偏头痛在青春期后会自发缓解,但如果在青春期发病,则更有可能持续至成年期。
我们进行了一项系统综述,旨在回答以下临床问题:儿童偏头痛急性发作的治疗及预防性治疗的效果如何?我们检索了:截至2010年6月的医学期刊数据库(Medline)、循证医学数据库(Embase)、考克兰图书馆(The Cochrane Library)以及其他重要数据库(临床证据综述会定期更新;请查看我们的网站获取本综述的最新版本)。我们纳入了来自美国食品药品监督管理局(FDA)和英国药品与保健品监管局(MHRA)等相关组织的危害警示。
我们发现了22项符合我们纳入标准的系统综述、随机对照试验或观察性研究。我们对干预措施的证据质量进行了GRADE评估。
在本系统综述中,我们呈现了以下干预措施有效性和安全性的相关信息:用于急性症状缓解(止吐药、磷酸可待因、非甾体抗炎药[NSAIDs]、对乙酰氨基酚和5-羟色胺1受体拮抗剂[如曲坦类药物])以及预防性治疗(β受体阻滞剂、饮食调整、苯噻啶、渐进性肌肉松弛、压力管理、热生物反馈和托吡酯)。